| Description |
| Product Type |
Product Size |
| Tablet |
20'S |
| Product Company |
| Mass Pharma |
Amlodipine 5mg
|
| Product Type |
Product Size |
| Tablets |
100'S |
| Product Company |
| Searle Pharma |
Amlodipine 80mg+Valsartan 5mg |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Sandoz |
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Himmel Pharma
|
Carboplatin 150mg/15ml |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Himmel Pharma
|
Topotecan 4mg/4ml
|
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Sanofi |
Furosemide and amiloride 5mg |
| Content | Amlodipine is in a class of medications called calcium channel blockers. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood to the heart
| Methyldopa is a centrally-acting alpha-2 adrenergic agonist used to manage hypertension alone or in combination with hydrochlorothiazide, and to treat hypertensive crises.
| Gemcitabine is a cytidine analog with two fluorine atoms.As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells. | Carboplatin is an alkylating agent used to treat advanced ovarian cancer.Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
| Topotecan is an antineoplastic agent used to treat ovarian cancer, small cell lung cancer, or cervical cancer.
| A combination of Furosemide and Amiloride is a diuretic which reduces the potassium loss of furosemide alone while avoiding the possible gastro-intestinal disturbances of potassium supplements.
|
Reviews
There are no reviews yet.